Diagnostics

Aerospace veteran John Slattery brings his expertise to Orbis International, aiming to elevate the mission of its unique Flying Eye Hospital.

A routine prenatal screen can now detect a virus that causes birth defects, offering a path to prevention and sparking calls to change medical guidelines.

LifeVantage heads to the ICR Conference to woo investors. Can its cellular health science overcome market headwinds and a volatile direct selling landscape?

With a top neurologist at the helm and a breakthrough platform, NanoMosaic aims to decentralize brain health diagnostics and reshape drug development.

A groundbreaking Duke trial combines a novel device to lure cancer cells with targeted immunotherapy, offering real-time tracking and new hope for patients.

A new partnership aims to eliminate lab management headaches for clinics, offering a single platform for ordering, results, and personalized treatment plans.

With its rare disease drug JURVIGO® in late-stage trials, Mezzion appoints a veteran leader to navigate the path to approval and commercialization.

With its massive data library and AI platforms, Tempus AI prepares for a pivotal presentation. What will CEO Eric Lefkofsky reveal to investors?

Bio-Rad's leadership will meet investors at the J.P. Morgan conference, facing questions on strategy and growth in a competitive, tech-driven market.

Inspira Technologies announces a landmark deal to acquire a liquid biopsy firm, securing a $15M investment at a $180M valuation to enter the cancer market.

Following a period of mixed financials, Neogen appoints new leaders to drive innovation and growth in its critical global food safety division.

A new joint venture between Corewell Health and Quest Diagnostics aims to reshape lab services across Michigan with a new high-tech facility and new efficiencies.

A new health initiative aims to fight chronic disease with personalized nutrition. But can data from your body truly fix a broken food system?

As it marks 32 years, Alexandria Real Estate Equities proves its resilience, dominating the market it created amid industry-wide headwinds.

LENZ Therapeutics partners with Lunatus to launch its breakthrough VIZZ™ presbyopia eye drops in the Middle East, targeting a vast, unmet medical need.

The new over-the-counter molecular test could deliver results in 30 minutes, aiming to revolutionize STI diagnostics and tap into a $1.5B market.

With pivotal Phase 2 data for its non-invasive skin cancer patch due in Q1, Medicus Pharma is advancing a diverse pipeline fueled by AI and strategic acquisitions.

A landmark $1.2M order for its advanced LineaDNA validates the firm's biotech arm, but can scientific success balance its new, volatile crypto strategy?

A new 10,000-sample 'skin library' collected by painless stickers aims to slash drug development time and costs for biopharmaceutical partners.

Gyre Therapeutics secures a pivotal conditional approval pathway in China for its novel liver fibrosis drug, offering hope for millions of hepatitis B patients.